|
ABOUT COMPANY
Altimmune, Inc., a clinical-stage biopharmaceutical company, focuses on the development of intranasal vaccines, immunomodulatory therapies, and treatments for liver disease. The company is headquartered in Gaithersburg, Maryland.
|
EARNINGS
Gross Profit (TTM): -25324291
Market Capitalization: 364006000
Operating Margin (TTM): -23.25
PE Ratio: None
PEG Ratio: 0
Profit Margin: 0
Revenue Per Share (TTM): 0.087
Revenue (TTM): 3445400
Quarterly Earnings Growth YOY: 0
Quarterly Revenue Growth YOY: -0.946
Trailing PE: -
|
DIVIDENDS
Diluted EPS (TTM): -2.11
Dividend Date: 2018-09-14
Dividend Per Share: None
Dividend Yield: 0%
EBITDA: -11790191
ExDividend Date: 2017-01-20
Forward Annual Dividend Rate:
Forward Annual Dividend Yield:
|